Candel Therapeutics
CADL
9.82
-0.05
-0.51%
Candel Therapeutics
US · CADL
#3461 by market cap
Listed 2021
9.82
-0.05
-0.51%
Live - 5344 symbols - heartbeat 318s ago
· 2026-10-08 09:13
Pre-market
9.82
-0.02%
After-hours
9.83
+0.10%
- Market cap
- 751.41M
- P/E (TTM)i
- -6.68
- P/Bi
- 5.96
- EPSi
- -0.72
- Div yieldi
- 0.00%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on CADL?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Margins
Key ratios & quality
- Enterprise valuei
- 679.26M
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 125.00K | 125.00K | 125.00K | 125.00K | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 2.56M | 5.18M | 10.67M | 14.06M | 13.89M | 14.06M | 17.77M |
| Research & development | 6.61M | 8.75M | 15.18M | 20.79M | 24.51M | 19.31M | 30.50M |
| Operating profit | -8.47M | -13.19M | -24.65M | -34.67M | -38.39M | -33.37M | -48.18M |
| Pretax profit | -8.24M | -17.68M | -36.12M | -18.79M | -37.94M | -55.18M | -38.18M |
| Tax | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -8.24M | -17.68M | -36.12M | -18.79M | -37.94M | -55.18M | -38.18M |
| Basic EPS | 0 | -1 | -2 | -1 | -1 | -2 | -1 |
| Diluted EPS | -0.44 | -0.94 | -1.91 | -0.65 | -1.31 | -1.74 | -0.72 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.11M | 4.19M | 4.75M | 4.72M | 6.44M | 6.95M |
| Research & development | 4.02M | 6.99M | 8.46M | 11.03M | 9.84M | 19.80M |
| Operating profit | -8.13M | -11.18M | -13.21M | -15.66M | -16.26M | -26.72M |
| Pretax profit | 7.38M | -4.80M | -11.27M | -29.50M | -8.86M | -38.91M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | 7.38M | -4.80M | -11.27M | -29.50M | -8.86M | -38.91M |
| Basic EPS | 0 | 0 | 0 | -1 | 0 | -1 |
| Diluted EPS | 0.13 | -0.09 | -0.21 | -0.54 | -0.14 | -0.52 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 45.21M | 35.15M | 84.95M | 71.95M | 36.80M | 103.80M | 121.39M |
| Cash & ST investments | 45.06M | 35.05M | 82.64M | 70.06M | 35.41M | 102.65M | 119.73M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 45.90M | 38.28M | 89.21M | 77.69M | 41.20M | 106.87M | 125.20M |
| Total current liabilities | 1.41M | 4.71M | 5.36M | 5.62M | 14.18M | 37.53M | 9.00M |
| Short-term debt | -- | 463.00K | -- | 464.00K | 9.41M | 10.46M | 445.00K |
| Long-term debt | 420.00K | 483.00K | 560.00K | 20.85M | 12.38M | 2.60M | 47.13M |
| Total liabilities | 53,939,000.00 | 61,844,000.00 | 25,068,000.00 | 29,977,000.00 | 28,456,000.00 | 40,539,000.00 | 73,273,000.00 |
| Total equity | -8.04M | -23.56M | 64.14M | 47.71M | 12.75M | 66.33M | 51.92M |
| Retained earnings | -26.49M | -44.17M | -80.30M | -99.09M | -137.03M | -192.21M | -230.39M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 93.15M | 103.61M | 90.13M | 121.39M | 197.75M | 204.16M |
| Cash & ST investments | 92.17M | 100.69M | 86.96M | 119.73M | 194.83M | 201.57M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 95.91M | 105.97M | 93.60M | 125.20M | 201.92M | 208.15M |
| Total current liabilities | 20.07M | 14.72M | 10.93M | 9.00M | 7.05M | 12.69M |
| Short-term debt | 9.75M | 7.30M | 4.66M | 445.00K | 453.00K | 461.00K |
| Long-term debt | 904.00K | 939.00K | 973.00K | 47.13M | 47.48M | 47.83M |
| Total liabilities | 21,230,000.00 | 15,758,000.00 | 13,474,000.00 | 73,273,000.00 | 63,891,000.00 | 82,019,000.00 |
| Total equity | 74.68M | 90.21M | 80.12M | 51.92M | 138.03M | 126.13M |
| Retained earnings | -184.83M | -189.62M | -200.89M | -230.39M | -239.25M | -278.15M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -5.18M | -9.07M | -22.22M | -31.42M | -34.24M | -27.02M | -38.31M |
| Depreciation & amortization | 43.00K | 91.00K | 232.00K | 778.00K | 960.00K | 990.00K | 845.00K |
| Free cash flow | -5.34M | -10.55M | -24.05M | -32.72M | -34.70M | -27.04M | -38.90M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 71.34M | -- | 0 | 101.76M | 19.37M |
| Ending cash balance | 5.45M | 35.32M | 83.07M | 70.32M | 35.68M | 102.92M | 120.15M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -8.62M | -8.89M | -10.24M | -10.57M | -18.04M | -17.18M |
| Depreciation & amortization | 245.00K | 242.00K | 195.00K | 163.00K | 149.00K | 171.00K |
| Free cash flow | -8.62M | -8.92M | -10.38M | -10.98M | -18.71M | -17.25M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 384.00K | 19.70M | -713.00K | 0 | 93.79M | 23.95M |
| Ending cash balance | 92.43M | 100.95M | 87.23M | 120.15M | 195.25M | 201.98M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -178.06 | -33.61 | -125.50 | -139.56 | -64.58 |
| ROA %i | -17.95 | -42.00 | -56.67 | -22.52 | -63.82 | -74.53 | -32.91 |
| ROIC %i | -- | -- | -173.34 | -27.70 | -70.60 | -93.96 | -44.23 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -108.26 |
| EBIT margin %i | -6,772.80 | -10,548.80 | -28,856.80 | -27,739.20 | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 32.06 | 7.46 | 15.84 | 12.81 | 2.59 | 2.77 | 13.49 |
| Quick ratioi | 31.96 | 7.44 | 15.41 | 12.48 | 2.50 | 2.74 | 13.31 |
| Debt / assetsi | 0.92 | 2.47 | 0.63 | 29.35 | 55.25 | 12.61 | 39.17 |
| LT debt / equityi | -- | -- | 0.87 | 46.81 | 104.79 | 4.54 | 93.58 |
| Interest coveragei | -- | -- | -680.58 | -- | -13.62 | -25.40 | -17.02 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -98.14 | -55.18 | -70.17 | -64.58 | -51.17 | -81.84 |
| ROA %i | -62.27 | -33.42 | -39.54 | -32.91 | -36.55 | -56.37 |
| ROIC %i | -70.18 | -43.13 | -56.23 | -44.23 | -40.56 | -64.82 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.64 | 7.04 | 8.25 | 13.49 | 28.05 | 16.09 |
| Quick ratioi | 4.59 | 6.84 | 7.96 | 13.31 | 27.63 | 15.89 |
| Debt / assetsi | 11.38 | 7.87 | 7.70 | 39.17 | 24.40 | 23.79 |
| LT debt / equityi | 1.55 | 1.16 | 3.18 | 93.58 | 35.37 | 38.89 |
| Interest coveragei | -21.62 | -14.60 | -19.82 | -17.02 | -15.12 | -17.77 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development, and potential commercialization of off-the-shelf viral immunotherapies that100.00%
Region
United States100.00%
Quote time 2026-10-08 09:13:45 · For reference only, not investment advice and not tailored to your situation.